Don’t compromise – choose the only topical skin adhesive (TSA) that has been tried, tested, and trusted for nearly 20 years.

The success of nearly every surgical procedure relies on strong, dependable wound closure.

The Innovator

DERMABOND ADVANCED® Topical Skin Adhesive is trusted by more surgeons than any other brand.*

Although a host of competitors have emerged since DERMABOND® Topical Skin Adhesive helped establish the TSA category in 1998, they haven’t been able to match the innovation, efficacy, and evidence behind the market leader.

The Others

- LiquiBand® Exceed™ Topical Skin Adhesive
- Skin Affix™ Topical Skin Adhesive
- SwiftSet™ Topical Skin Adhesive
- SursiSeal® Topical Skin Adhesive
- Derma+Flex® QS™ High Viscosity Tissue Adhesive
- Exofin® High Viscosity Tissue Adhesive
- Histoacryl® Topical Skin Adhesive
- ACTABOND™ Topical Skin Adhesive

*Market-leading claim based on US unit market share data as of September 2016. The third party trademarks used herein are trademarks of their respective owners.
The Innovation

Medical device innovation begins with an idea for improving patient care, and then requires a massive commitment to research and development to make it a reality. In 1998, DERMABOND® Topical Skin Adhesive was introduced to the market, a breakthrough that transformed surgical wound closure.

SUSTAINED INNOVATION HAS GIVEN RISE TO THE DERMABOND® PORTFOLIO, A DIVERSE FAMILY OF SKIN CLOSURE SOLUTIONS FOR A WIDE VARIETY OF CLINICAL NEEDS

<table>
<thead>
<tr>
<th>Year</th>
<th>Product Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>DERMABOND Adhesive</td>
</tr>
<tr>
<td>2002</td>
<td>DERMABOND Adhesive (High viscosity)</td>
</tr>
<tr>
<td>2006</td>
<td>DERMABOND® Mini Topical Skin Adhesive</td>
</tr>
<tr>
<td>2011</td>
<td>DERMABOND ADVANCED® Topical Skin Adhesive &amp; DERMABOND® PRINEO® Skin Closure System (60 cm)</td>
</tr>
<tr>
<td>2015</td>
<td>DERMABOND® PRINEO® Skin Closure System (22 cm)</td>
</tr>
</tbody>
</table>

The Efficacy

DERMABOND ADVANCED Adhesive is more than just a 2-octyl monomer, and every component is essential to the benefits it provides. This efficacy is enabled by Ethicon’s proven ability to consistently manufacture millions of units each year while ensuring customers receive a product that meets strict quality guidelines every time.

Precisely balanced formula provides strong, flexible skin closure plus microbial barrier protection³,⁵

Highly purified 2-octylcyanoacrylate monomer provides strength and flexibility³,⁵

Chemical initiator ensures consistent, reliable polymerization times³

Formulation additives including a plasticizer and a thickener enhance strength, flexibility, and skin adherence⁴

TSAs: More than just a monomer

Several competitors have claimed similar benefits just because they share the same 2-octyl monomer, and some have even used studies of DERMABOND Adhesive to support their efficacy claims.⁶ However, no competitor has the same formula as DERMABOND ADVANCED Adhesive, which means they cannot be expected to perform the same.
Advanced Applicator

The adhesive is only half of the story. By harnessing nearly two decades of TSA expertise, every feature of the 4th generation DERMABOND ADVANCED® Topical Skin Adhesive applicator is designed to optimize surgeon experience and enhance product delivery.

- Embedded initiator technology to avoid clogging
- .7 mL formulation to close wounds up to 15 cm
- Faster drying time in a single layer application
- Cutting edge design for controlled fine and wide line application
- Advanced silicone technology for easy activation and expression of adhesive
- Ergonomically designed device

The Evidence

Ultimately, product efficacy can only be demonstrated through clinical trials and real-world patient studies. When it’s time for wound closure, reach for DERMABOND ADVANCED Adhesive – the product supported by far more clinical data than any competitor.\(^1\,9\,10\)†‡§

DERMABOND ADVANCED Adhesive is supported by substantially more randomized controlled trials (RCTs) than the top 6 competitors combined.\(^1\,9\,10\)†‡§

Large retrospective analyses support the clinical and economic benefits of DERMABOND ADVANCED Adhesive.

**LENGTH OF STAY**

9 days with DERMABOND Adhesive

13 days without DERMABOND Adhesive

In a retrospective study of 1,360 patients in CABG surgery, postoperative hospital stay was **reduced from 13 days to 9 days** when DERMABOND ADVANCED Adhesive was used in addition to conventional sutures.\(^11\)

**TOTAL C-SECTION HOSPITALIZATION COSTS**

$5,594 Staples

$5,572 Sutures

$500

$5,010 DERMABOND Adhesive

In a retrospective database study of 155,557 C-sections, hospitalization costs were **$500 lower** for the DERMABOND ADVANCED Adhesive skin closure group vs. staples or sutures alone.\(^12\)

*Compared to DERMABOND® Topical Skin Adhesive.
**DERMABOND ADVANCED Adhesive tests equivalent or superior to DERMABOND Adhesive in head-to-head testing for microbial barrier, wound bursting strength, tensile strength, flexibility, durability, viscosity, drying time, water vapor transmission rate, water resistance, and physician satisfaction.
†Top 6 US competitors include LiquiBand®, Skin Affix®, SwiftSet®, SurgiSeal®, Derma+Flex® QS™, and Histoacryl®.
‡Based on published literature in PubMed as of March 7, 2017, using only RCTs that evaluated the use of the product in a manner consistent with intended indication.
§Top 6 US competitors include LiquiBand®, Skin Affix®, SwiftSet®, SurgiSeal®, Derma+Flex® QS™, and Histoacryl®.
\(\)Premier Perspective™ Comparative Database.
Wound closure is key to a great surgical outcome.

**Don’t settle for less** than the innovation, efficacy, and evidence behind DERMABOND ADVANCED® Topical Skin Adhesive.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.